Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation
Makaleler > Tam Makale · 2016
Yazarlar: M. Teresa DE LA MORENA, David LEONARD, Troy R. Torgerson, Otavio CABRAL-MARQUES, Mary SLATTER, Asghar AGHAMOHAMMADI, Sharat CHANDRA, Luis Murguia-Favela, Francisco A. Bonilla, Maria KANARIOU, Rongras DAMRONGWATANASUK, Caroline Y. KUO, Christopher C. DVORAK, Isabelle MEYTS, Karin CHEN, Lisa Kobrynski, Neena KAPOOR, Darko RICHTER, Daniela DIGIOVANNI, Fatima Dhalla, Evangelia FARMAKI, Carsten SPECKMANN, Teresa ESPANOL, Anna SHCHERBINA, Imelda Celine HANSON, Jiri LITZMAN, John M. ROUTES, Melanie Wong, Ramsay FULEIHAN, Suranjith L. Seneviratne, Trudy N. SMALL, Ales JANDA, Liliana BEZRODNIK, Reinhard SEGER, Andrea Gomez RACCIO, J. David M. EDGAR, Janet Chou, Jordan K. ABBOTT, Joris van Montfrans, Luis Ignacio GONZALEZ-GRANADO, Nancy Bunin, Necil KÜTÜKÇÜLER, Paul GRAY, Gisela SEMINARIO, Srdjan PASIC, Victor AQUINO, Christian WYSOCKI, Hassan ABOLHASSANI, Morna DORSEY, Charlotte CUNNINGHAM-RUNDLES, Alan P. Knutsen, John Sleasman, Beatriz Tavares Costa CARVALHO, Antonio Condino-Neto, Eyal GRUNEBAUM, Helen CHAPEL, Hans D. OCHS, Alexandra FILIPOVICH, Mort COWAN, Andrew GENNERY, Andrew CANT, Luigi D. NOTARANGELO, Chaim M. ROIFMAN
Journal of Allergy and Clinical Immunology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2016, cilt 139, ss 1282-1292
DOI: 10.1016/j.jaci.2016.07.039
Özet
Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients.